Cabaletta surges after early data on cell therapy for autoimmune skin disease

Cabaletta Bio

09/10/2025 17:36

** Shares of drug developer Cabaletta Bio CABA.O jump 25.1% to $2.95

** Company has been testing a new cell-based treatment called rese-cel for pemphigus vulgaris, a rare autoimmune disease that causes painful blisters on the skin and mucous membranes

** In a small early-stage trial, three patients with severe, treatment-resistant cases received the therapy

** Two of the patients saw almost complete relief from symptoms, and all three were able to stop using other immune-suppressing drugs or reduce their steroid use

** The therapy also showed strong cell expansion without preconditioning — a process usually required to prepare the body for cell therapy

** Company also confirmed that its trials for other conditions like lupus, myositis, scleroderma, and myasthenia gravis are fully enrolled

** Including session moves, stock up 9.9% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))